$RANI News

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics Partners With PegBio To Mull Delivery Of Multiple Novel Candidates From PegBio's Obesity And Metabolic Disease Pipeline Through RaniPill Platform

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/Share

Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Rani Therapeutics Q4 Earnings Call Highlights

RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) Posts Q4 Revenue Miss Amid $1 Billion Chugai Partnership and $60M Financing

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript